Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in ChinaGlobeNewswire·Jul 19 at 09:15 PM06086+5.88%NVO-8.78%
Fangzhou Inc. Shareholders Approve All AGM Resolutions and Capital MandatesTip Ranks·Jun 16 at 06:01 PM06086+5.88%
Fangzhou Showcases AI-Powered Chronic Disease Management Solution With Tencent Health at Tencent Cloud ConferenceGlobeNewswire·Jun 5 at 01:48 AM06086+5.88%
Citi lowers the target price for FANGZHOU JIANKE to 7.5 yuan, stating that its value is severely underestimatedAASTOCKS·Mar 23 at 09:17 PM06086+5.88%513120+0.70%
"Performance" FANGZHOU JIANKE achieved a net profit of 10.86 million RMB for the year, turning a loss into a profitAASTOCKS·Mar 19 at 12:02 PM06086+5.88%
Fangzhou Swings to Profit as Revenue Surges and Digital Health Platform ExpandsTip Ranks·Mar 19 at 10:11 AM06086+5.88%00700+0.72%
Fangzhou, Youcare Partner To Advance AI In Chronic Disease Carerttnews·Feb 28 at 10:54 PM06086+5.88%510660+0.86%
XS LLM named a top healthcare model for 2026 in China, integrates 5 agents in chronic disease management cycle.Unusual Whales·Feb 9 at 08:30 PM510660+0.86%589720+0.35%
Hong Kong Stock Movement Quick Report: Video and Financial Sectors Strongly Rebound, HMVOD Soars 76% Leading the MarketHK Stock Alerts·Feb 3 at 12:00 AM081030.00%08059+9.09%
Hong Kong Stock Midday Review | The Hang Seng Index slightly rises during the session, with active Internet and AI concepts; FANGZHOU JIANKE rises over 16%Market Pulse·Feb 2 at 10:13 PM00100+13.15%02039-1.17%
